The National Agency for Food and Drugs Administration and Control has publicly announced the recall of G Fuel brand Energy Drinks by T&E Imports and GPAE Trading Corp due to their elevated caffeine content.
This announcement, designated as public alert No. 034/2023, was made by the Director-General of NAFDAC, Prof. Mojisola Adeyeye, in Abuja on Thursday.
Adeyeye mentioned that the Netherlands Food and Consumer Product Safety Authority and the Canadian Food Inspection Agency have also recalled the same product.
Prof. Adeyeye emphasized that the consumption of products with high caffeine levels can lead to adverse effects, including headaches, insomnia, irritability, and nervousness.
She pointed out that even individuals with a low sensitivity to caffeine may experience these adverse effects at minimal consumption levels. Additionally, she issued a warning to pregnant women, advising them against consuming these products due to the potential health risks, such as an increased likelihood of miscarriage and the possibility of delivering a baby with low birth weight.
The Director-General also highlighted that the affected products lack clear cautionary statements regarding daily consumption limits and are available for purchase online.
“The product is not registered by NAFDAC, which implored consumers and retailers to refrain from using, selling, serving, or distributing the implicated product.
“Members of the public are encouraged to report any suspicion of distribution and sale of unwholesome packaged food products to the nearest NAFDAC office.
“NAFDAC could also be reached on 0800-162-3322 or via email: sf.alert@nafdac.gov.ng.
“Healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of any substandard NAFDAC-regulated product to the nearest NAFDAC office.
“NAFDAC could also be reached through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med-safety application available for download on Android and IOS stores.
“The public could also reach NAFDAC via e-mail at pharmacovigilance@nafdac.gov.ng,” she added
